

**Amendments to the Claims:**

Please amend claim 11.


This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1.-10. (Cancelled)

11. (Currently Amended) An *in vitro* method of inhibiting for assessing the ability of a compound to inhibit VEGF production in a cell from a tumor of a patient in need of treatment, comprising the steps of:

(a) contacting said cell with an effective amount of an active compound; said compound of the formula I



(I)

wherein:

A is a four to seven membered heterocyclic ring, aromatic or non-aromatic, containing one or more nitrogen, oxygen or sulfur atoms in one or more heterocyclic rings and optionally substituted on the carbon atoms with halogens, alkyls which may be optionally substituted by halogen, amino, hydroxy or cyano groups, aryls, an aromatic or non-aromatic 5- or 6-membered heterocyclic ring containing at least one atom of oxygen, sulfur or nitrogen, hydroxy, amino, monoalkylamino, monoarylamino, bisalkylamino, bisarylamino, (alkyl)(aryl)amino, carbonylamino, alkyl(carbonyl)amino, alkoxycarbonyl, carboxy, cyano groups or, on the nitrogen atoms, with alkyl, aryl, arylalkyl groups or with oxygen atoms to form N-oxides; said four to seven membered heterocyclic ring being optionally fused to one or two

Reply & Amendment to Final Office Action dated January 08, 2009 with RCE

aryl, heteroaryl or cycloalkyl groups, in their turn optionally substituted with amino, C<sub>1</sub>-C<sub>8</sub> monoalkylamino, monoarylamino, C<sub>1</sub>-C<sub>8</sub> bisalkylamino, aryloxy, halogens, alkyl, hydroxy, alkoxycarbonyl, carboxy, cyano groups; said aryl, heteroaryl or cycloalkyl groups being optionally partially saturated or unsaturated, respectively;

R1-R4 are independently selected from hydrogen, C<sub>1</sub>-C<sub>20</sub> alkyl optionally interrupted by one or more heteroatoms, hydroxy, C<sub>1</sub>-C<sub>8</sub> alkoxy, C<sub>1</sub>-C<sub>8</sub> alkoxy optionally substituted with hydroxyl, amino, thio, cyano, carboxy, carboxylic esters, or amides, C<sub>1</sub>-C<sub>8</sub> haloalkoxy, phenoxy, aralkoxy, C<sub>1</sub>-C<sub>8</sub> acyloxy, amino, C<sub>1</sub>-C<sub>8</sub> monoalkylamino, C<sub>1</sub>-C<sub>8</sub> bisalkylamino, C<sub>1</sub>-C<sub>8</sub> acylamino, C<sub>1</sub>-C<sub>8</sub> alkylsulfonylamino, aroylamino, halogen, nitro, cyano, trifluoromethyl, carboxy, C<sub>1</sub>-C<sub>3</sub> alkoxycarbonyl, a R<sub>a</sub>R<sub>b</sub>N(CH<sub>2</sub>)<sub>n</sub>C(=O)- group where R<sub>a</sub> and R<sub>b</sub> are independently hydrogen, C<sub>1</sub>-C<sub>3</sub> alkyl or R<sub>a</sub> and R<sub>b</sub> together with the nitrogen atom they are linked to form a pyrrolidino, piperidino, piperazino or morpholino ring and n = 0 or an integer 2 to 4, sulfonyl, mercapto, C<sub>1</sub>-C<sub>4</sub> alkylthio, C<sub>1</sub>-C<sub>4</sub> alkylsulfonyl, C<sub>1</sub>-C<sub>4</sub> alkylsulfinyl, aminosulfonyl, C<sub>1</sub>-C<sub>3</sub> alkylaminosulfonyl, a group CH<sub>2</sub>NR<sub>a</sub>R<sub>b</sub>, or, taken together with the atoms to which they are attached, R1 and R2 or R2 and R3, or R3 and R4 form an additional aromatic or heteroaromatic ring;

R5 is hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>7</sub>-C<sub>10</sub> aralkyl,

or a pharmaceutically acceptable salt, solvate, amide, ester, N-oxide, chemically protected form, and prodrug thereof; and

(b) determining whether VEGF production is inhibited.

12.-14. (Cancelled)

Reply & Amendment to Final Office Action dated January 08, 2009 with RCE

15. (Previously Presented) The method according to claim 11 wherein the heterocyclic ring A of said compound is selected from pyrrolyl, furanyl, thiophenyl, pyrazolyl, thiazolyl, indolyl, oxazolyl, imidazolyl, isothiazolyl, isoxazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, tetrazolyl, pyrimidinyl, pyridazinyl, pyrazinyl, 1,2,4-triazinyl, benzofuranyl, indazolyl, carbazolyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, benzotriazolyl, quinoliny, isoquinoliny, cinnoliny, quinoxaliny, quinazoliny, phthalazinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl, purinyl, pteridinyl, benzo[d]imidazo[2,1-b]thiazolyl, 4,5-dihydro-naphtho[1,2-d]thiazolyl, imidazo[1,2-a]pyridinyl.


16. (Previously Presented) The method according to claim 15 wherein A is selected from thiazolyl, 1,3,4-oxadiazolyl, 1,3,4-thiadiazolyl, benzothiazolyl, benzimidazolyl, benzoxazolyl, benzo[d]imidazo[2,1-b]thiazolyl, 4,5-dihydro-naphtho[1,2-d]thiazolyl, imidazo[1,2-a]pyridinyl.

17. (Previously Presented) The method according to claim 16 wherein A is selected from thiazolyl, wherein the thiazole ring is connected to the 3-position of the coumarin ring through the 2-, 4- or 5-position.


Reply & Amendment to Final Office Action dated January 08, 2009 with RCE

18. (Previously Presented) The method according to claim 11 wherein A is a 2-thiazolyl, 4-thiazolyl or 5-thiazolyl residue, 1,3,4-oxadiazol-2-yl, 1,3,4-thiadiazol-2-yl, benzothiazol-2-yl, benzimidazol-2-yl, benzoxazol-2-yl,


benzo[d]imidazo[2,1-b]thiazol-2-yl of formula



4,5-dihydro-naphtho[1,2-d]thiazole-2-yl of formula



imidazo[1,2-a]pyridine-2-yl of formula



19. (Previously Presented) The method according to any one of claims 11, 15, 16, 17 or 18 wherein R1, R2, R3, and R4 are hydroxy, C<sub>1</sub>-C<sub>8</sub> alkoxy, amino, C<sub>1</sub>-C<sub>8</sub> monoalkylamino, C<sub>1</sub>-C<sub>8</sub> bisalkylamino.

20. (Previously Presented) The method according to claim 19 wherein R1, R2, R3, and R4 are hydroxy or diethylamino.

21. (Previously Presented) The method according to claim 11 wherein said compound is 3-[4-phenylthiazol-2-yl]-7-(N,N-diethylamino)-chromen-2-one.